Please login to the form below
melanoma
This page shows the latest melanoma news and features for those working in and with pharma, biotech and healthcare.
Keytruda growth helps Merck to offset COVID-19 impact in Q3
other areas including adjuvant melanoma and bladder cancer.
Latest news
-
Seres’ microbiome-based therapy hits the mark in phase 3
This includes research into Seres’ phase 1b candidate SER-401, which is being investigated for its ability to improve the clinical outcomes of metastatic melanoma patients treated with currently-available immunotherapies.
-
Roche’s Tecentriq combo scores FDA approval for melanoma
Tecentriq, plus MEK inhibitor Cotellic (cobimetinib) and BRAF inhibitor Zelboraf (vemurafenib), has been backed for the treatment of BRAF V600 mutation-positive advanced melanoma patients. ... The FDA approval of this Tecentriq combination represents an
-
Roche’s PD-L1 inhibitor Tecentriq approved in China for SCLC
In addition to lung cancer, Merck’s drug is approved for a host of other cancer types, including in China for advanced melanoma.
-
Newly-listed BioNTech buys Neon to boost cell therapy assets
The lead drug in that programme is NEO-PTC-01, a T-cell therapy targeting shares RAS oncogenes in solid tumours, initially heading for a clinical trial on metastatic melanoma patients
-
Lilly ends $1.4bn deal with immuno-oncology biotech NextCure
The trial included patients with non-small cell lung cancer, ovarian cancer, melanoma, breast cancer and colorectal cancer and all were heavily pre-treated with a median of three prior therapies.
More from news
Approximately 82 fully matching, plus 291 partially matching documents found.
Latest Intelligence
-
Surviving cancer: a new era for patients
In European patients, the average five-year relative survival rate was 83% for melanoma, 83% for prostate cancer, 82% for breast cancer and 57% for colon cancer.
-
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
targets of small cell lung cancer and melanoma in adults, while its licensing became embroiled in a royalties dispute.
-
Immuno-oncology in 2019: the rapid evolution continues
BMS led the charge when Opdivo became the first in its class to gain approval (in metastatic melanoma in December 2014 in Japan), but Merck &Co’s Keytruda has emerged as
-
Is China ready for a pharmaceutical gold rush?
China’s millions of tobacco smokers make for a large market, which may be why BMS filed for approval in lung cancer treatment, rather than melanoma, the leading indication in other
-
Combined immunotherapies – potential and pitfalls
The recent failed phase 3 trial of a combination of MSD’s monoclonal antibody Keytruda (pembrolizumab) and InCyte Corporation’s epacadostat in metastatic melanoma is a case in point he says.
More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.
Latest appointments
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
Since its first approval in 2014 for the treatment of advanced melanoma with BRAF mutations, Keytruda has become a blockbuster immunotherapy as well as introducing a new standard-of-care for
-
Industry appointments
Most recently, Hassan built the oncology-focused biology, preclinical and biomarker units for Immunocore, overseeing early development and the first-in-human trial of a TCR based biologic targeting a melanoma
-
Packer Forbes appoints Jade McCudden
McCudden has worked across a number of disease areas including hepatitis C, anticoagulation, Alzheimer's disease, women's health, melanoma and nicotine replacement therapy.
-
Array appoints Victor Sandor chief medical officer
This includes the Colorado, US-based company's binimetinic, a MEK inhibitor in phase III trials for ovarian cancer and melanoma, and filanesib, a KSP inhibitor for multiple myeloma.
-
Bruno Strigini leaves Merck & Co for Novartis
Leading the field though is Strigini's former company Merck &Co, which has already filed MK-3475 in the US to treat advanced melanoma.
More from appointments
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest from PMHub
-
University spin-out fund makes half a million pound first investments
They will use the cash boost to enable a market launch in the UK and prepare for international expansion with the commercialisation of their new melanoma test AMBLor in the USA
-
Great creative is effective creative. And effective creative is affective creative
One shining example of this can be found in the Melanoma Likes Me campaign from WPP in Australia:. ... Then, the creepy online persona ‘Melanoma’ – would ‘like’, ‘follow’ and comment, in real time.
-
Using Healthtech to Deliver Better Patient Outcomes
In this recent episode of Impetus Digital‘s Fireside Chat series, I sit down with Peter Birch, General Manager (Asia Pacific) at MetaOptima Technologies &host of the “Talking HealthTech Podcast.” We discuss a whole range of topics, including
-
If our patients are diverse, why are clinical trials so white?
According to the largest study (to date) in different racial and ethnic populations across the US, there was no evidence to support the association of UV exposure and melanoma incidence in ... black or Hispanic populations – studies assessing the
-
Lucid Group expands its presence in the north-west with six new hires
and the response of uveal melanoma.
More from PMHub
Approximately 3 fully matching, plus 14 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Medical Editor
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Account Director
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- GSK’s PD-1 inhibitor dostarlimab shows updated promise in dMMR solid tumours
- New study identifies drugs that are safe to use in COVID-19 treatment
- CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers
- Trial combining British and Russian COVID-19 vaccines could begin in February
- Merck ends its COVID-19 vaccine programme after disappointing early trial results
- AstraZeneca reduces initial COVID-19 vaccine deliveries to the EU
- Pfizer/BioNTech reach vaccine supply agreement with COVAX
- BMS gains FDA approval for second Opdivo combo in kidney cancer
- An EU emergency health fund to limit the impact of future crises
- Mistrust in medical research: a patient perspective
PMHub
Spirit
We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...
Latest intelligence
- An EU emergency health fund to limit the impact of future crises
- Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
Quick links
Infographics
